Growth Metrics

Novavax (NVAX) Total Current Liabilities (2016 - 2025)

Historic Total Current Liabilities for Novavax (NVAX) over the last 17 years, with Q3 2025 value amounting to $429.9 million.

  • Novavax's Total Current Liabilities fell 6360.12% to $429.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $429.9 million, marking a year-over-year decrease of 6360.12%. This contributed to the annual value of $1.2 billion for FY2024, which is 2939.95% down from last year.
  • According to the latest figures from Q3 2025, Novavax's Total Current Liabilities is $429.9 million, which was down 6360.12% from $389.1 million recorded in Q2 2025.
  • Novavax's 5-year Total Current Liabilities high stood at $2.5 billion for Q4 2022, and its period low was $389.1 million during Q2 2025.
  • Over the past 5 years, Novavax's median Total Current Liabilities value was $1.6 billion (recorded in 2023), while the average stood at $1.5 billion.
  • In the last 5 years, Novavax's Total Current Liabilities soared by 626684.75% in 2021 and then tumbled by 6639.02% in 2025.
  • Over the past 5 years, Novavax's Total Current Liabilities (Quarter) stood at $2.4 billion in 2021, then grew by 2.91% to $2.5 billion in 2022, then plummeted by 33.53% to $1.6 billion in 2023, then decreased by 29.4% to $1.2 billion in 2024, then tumbled by 62.76% to $429.9 million in 2025.
  • Its Total Current Liabilities was $429.9 million in Q3 2025, compared to $389.1 million in Q2 2025 and $422.2 million in Q1 2025.